Evidence map›Paper›PMID 26806818›Full record

ArticleJournal of hepatology2016

Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.

Ingrid Lua, Yuchang Li, Jessica A Zagory, Kasper S Wang, Samuel W French, Jean Sévigny, Kinji Asahina

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 148 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Challenges ofFrontiers in cell and developmental biology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Theranostics · 2024
    Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ingrid LuaSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yuchang LiSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jessica A ZagoryDevelopmental Biology, Regenerative Medicine and Stem Cell Program, Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Kasper S WangDevelopmental Biology, Regenerative Medicine and Stem Cell Program, Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Samuel W FrenchDepartment of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.
Jean SévignyDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine, Université Laval, Québec QC G1V 0A6, Canada; Centre de Recherche du CHU de Québec - Université Laval, CHUL, Québec QC G1V 4G2, Canada.
Kinji AsahinaSouthern California Research Center for ALPD and Cirrhosis, Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: asahina@med.usc.edu.
University of Southern California · USChildren's Hospital of Los Angeles · USCentre hospitalier de l'Université Laval · CAUCLA Medical Center · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8M
NON-PARENCHYMAL LIVER CELL CORER24AA012885 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TSUKAMOTO, HIDEKAZU · 2001 to 2025
$8.1M
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChilLDRen) Clinical Centers.U01DK084538 · NIDDK · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KOHLI, ROHIT · 2009 to 2023
$4.8M
Training in Developmental Biology, Stem Cells and RegenerationT32HD060549 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Gage D Crump · 2011 to 2026
$2.5M
Contribution of the mesothelium to alcohol-induced liver fibrosisR01AA020753 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ASAHINA, KINJI · 2011 to 2015
$1.7M
NIAAA NIH HHS P50 AA011999NIAAA NIH HHS P50AA011999NIAAA NIH HHS R01 AA020753NIAAA NIH HHS R01AA020753NIAAA NIH HHS R24 AA012885NICHD NIH HHS T32 HD060549NICHD NIH HHS T32HD060549NIDDK NIH HHS P30 DK048522NIDDK NIH HHS P30DK048522NIDDK NIH HHS U01 DK084538NIDDK NIH HHS U01DK084538
6 · The paper itself

Abstract

BACKGROUND &

aimsContribution of hepatic stellate cells (HSCs), portal fibroblasts (PFs), and mesothelial cells (MCs) to myofibroblasts is not fully understood due to insufficient availability of markers and isolation methods. The present study aimed to isolate these cells, characterize their phenotypes, and examine their contribution to myofibroblasts in liver fibrosis.

methodsLiver fibrosis was induced in Collagen1a1-green fluorescent protein (Col1a1(GFP)) mice by bile duct ligation (BDL), 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet, or CCl4 injections. Combining vitamin A (VitA) lipid autofluorescence and expression of GFP and glycoprotein M6a (GPM6A), we separated HSCs, PFs, and MCs from normal and fibrotic livers by fluorescence-activated cell sorting (FACS).

resultsNormal Col1a1(GFP) livers broadly expressed GFP in HSCs, PFs, and MCs. Isolated VitA+ HSCs expressed reelin, whereas VitA-GFP+GPM6A- PFs expressed ectonucleoside triphosphate diphosphohydrolase-2 and elastin. VitA-GFP+GPM6A+ MCs expressed keratin 19, mesothelin, and uroplakin 1b. Transforming growth factor (TGF)-β1 treatment induced the transformation of HSCs, PFs, and MCs into myofibroblasts in culture. TGF-β1 suppressed cyclin D1 mRNA expression in PFs but not in HSCs and MCs. In biliary fibrosis, PFs adjacent to the bile duct expressed α-smooth muscle actin. FACS analysis revealed that HSCs are the major source of GFP+ myofibroblasts in the injured Col1a1(GFP) mice after DDC or CCl4 treatment. Although PFs partly contributed to GFP+ myofibroblasts in the BDL model, HSCs were still dominant source of myofibroblasts.

conclusionHSCs, PFs, and MCs have distinct phenotypes, and PFs partly contribute to myofibroblasts in the portal triad in biliary fibrosis.

Indexed as

AnimalsCells, CulturedEpitheliumFibroblastsFlow CytometryHepatic Stellate CellsLiverLiver Cirrhosis, ExperimentalMesothelinMicePortal VeinReelin ProteinMesothelinReelin ProteinEntpd2FibrosisGpm6aMesothelinMyofibroblastsReelinUroplakin

Identifiers

PMID26806818
PMCPMC4834254
OpenAlexW2272188229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.